Verona Pharma PLC ADR (NASDAQ:VRNA) — Market Cap & Net Worth
Market Cap & Net Worth: Verona Pharma PLC ADR (VRNA)
Verona Pharma PLC ADR (NASDAQ:VRNA) has a market capitalization of $7.31 Billion ($7.31 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2760 globally and #981 in its home market, demonstrating a -2.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verona Pharma PLC ADR's stock price $86.00 by its total outstanding shares 84978881 (84.98 Million). See Verona Pharma PLC ADR capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Verona Pharma PLC ADR Market Cap History: 2017 to 2025
Verona Pharma PLC ADR's market capitalization history from 2017 to 2025. Data shows growth from $1.01 Billion to $7.31 Billion (24.24% CAGR).
Index Memberships
Verona Pharma PLC ADR is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.30% | #61 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.02% | #310 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.42% | #41 of 263 |
Weight: Verona Pharma PLC ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Verona Pharma PLC ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verona Pharma PLC ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
116.86x
Verona Pharma PLC ADR's market cap is 116.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.01 Billion | $1.84 Million | -$20.50 Million | 547.95x | N/A |
| 2018 | $820.05 Million | $2.78K | -$19.90 Million | 294662.67x | N/A |
| 2019 | $488.63 Million | $2.35K | -$30.62 Million | 207838.61x | N/A |
| 2020 | $594.85 Million | $2.35K | -$47.64 Million | 253020.91x | N/A |
| 2021 | $571.06 Million | $29.58 Million | -$41.09 Million | 19.31x | N/A |
| 2022 | $2.22 Billion | $378.87K | -$56.83 Million | 5860.91x | N/A |
| 2023 | $1.69 Billion | $458.00K | -$42.65 Million | 3688.60x | N/A |
| 2024 | $3.95 Billion | $33.77 Million | -$138.52 Million | 116.86x | N/A |
Competitor Companies of VRNA by Market Capitalization
Companies near Verona Pharma PLC ADR in the global market cap rankings as of August 1, 2026.
Key companies related to Verona Pharma PLC ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Verona Pharma PLC ADR Historical Marketcap From 2017 to 2025
Between 2017 and today, Verona Pharma PLC ADR's market cap moved from $1.01 Billion to $ 7.31 Billion, with a yearly change of 24.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $7.31 Billion | +85.19% |
| 2024 | $3.95 Billion | +133.60% |
| 2023 | $1.69 Billion | -23.92% |
| 2022 | $2.22 Billion | +288.84% |
| 2021 | $571.06 Million | -4.00% |
| 2020 | $594.85 Million | +21.74% |
| 2019 | $488.63 Million | -40.41% |
| 2018 | $820.05 Million | -18.71% |
| 2017 | $1.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Verona Pharma PLC ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.31 Billion USD |
| MoneyControl | $7.31 Billion USD |
| MarketWatch | $7.31 Billion USD |
| marketcap.company | $7.31 Billion USD |
| Reuters | $7.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more